Citations

Clear

1325 citation(s) found for "Mayo, Angela".

Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT).
Burtis, Michelle, Thanarajasingam, Gita , Warsame, Rahma , Thompson, Carrie A. , Yost, Kathleen J. , Ansell, Stephen M. , Bennani, Nabila Nora, Johnston, Patrick B. , Kumar, Shaji , Sidana, Surbhi , Dueck, Amylou C. , Burtis, Michelle, Griffin, Joan M. , Cheville, Andrea , Gertz, Morie A. , Dispenzieri, Angela , Villasboas, José C. , Paludo, Jonas , Rajkumar, S. Vincent , Siddiqui, Mustaqeem , Lin, Yi

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 6594-6594

10.1200/jco.2019.37.15_suppl.6594 Get It

6594 Background: Given the significant short-term adverse effects of CAR-T cell therapy, it is important to evaluate its impact on QOL of patients in addition to efficacy, compared with established forms of cellular therapy like SCT. Methods: QOL was evaluated prospectively in patients undergoing CAR-T therapy, autoSCT & alloSCT for hematologic malignancies. QOL was assessed with FACT-G at baseline, 2 weeks and monthly for 6 months thereafter. Functional well-being (FWB), physical WB (PWB) emotional WB (EWB) & social WB (SWB) and change over time were compared across groups. Results: 45 patients were recruited (CAR-T: 10; Auto SCT: 22; Allo SCT: 13) with follow up for 2 weeks & 1 month available for 23 &15 patients, respectively (Table). There was no statistically significant difference in baseline total QOL scores (p=0.13), though scores were lower in the alloSCT group (85,84,68). EWB &FWB were numerically higher in the CAR-T group, followed by autoSCT group. At 2 weeks, overall QOL decreased by only 2 points in CAR-T group vs. 22 & 18 points in auto & alloSCT groups (p=0.09). Change in PWB vs. baseline was less pronounced in the CAR-T group (-1, -9, -13, p=0.03). At 1 month, overall QOL was 6 points lower than baseline in CAR-T group vs. 3 and 14 points lower in auto & alloSCT groups, respectively (p=0.34). Importantly, PWB had at least returned to baseline in the CAR-T group. Conclusions: Preliminary data show that patients undergoing CAR-T cell therapy do not experience a more significant decline in QOL compared with auto & allo SCT, and may experience fewer physical side effects in the short-term. Accrual & follow-up are ongoing. [Table: see text]
Magnetic Resonance Elastography of Liver in Light Chain Amyloidosis
Venkatesh, Sudhakar K. , Hoodeshenas, Safa, Venkatesh, Sandeep H., Dispenzieri, Angela, Gertz, Morie A. , Torbenson, Michael S., Ehman, Richard L., Gertz, Morie A , Venkatesh, Sudhakar K , Hoodeshenas, Safa , Venkatesh, Sandeep Halagatti, Dispenzieri, Angela , Torbenson, Michael S., Ehman, Richard L.

Mayo Clinic

Journal of Clinical Medicine | May 24, 2019 | Volume: 8 | Issue: 5 | Pages: 739

10.3390/jcm8050739 | PMID 31126105 Get It

In this paper, we present our preliminary findings regarding magnetic resonance elastography (MRE) on the livers of 10 patients with systemic amyloidosis. Mean liver stiffness measurements (LSM) and spleen stiffness measurements (SSM) were obtained. Magnetic resonance imaging (MRI) images were analyzed for the distribution pattern of amyloid deposition. Pearson correlation analysis was performed in order to study the correlation between LSM, SSM, liver span, liver volume, spleen span, spleen volume, serum alkaline phosphatase (ALP), N-terminal pro b-type natriuretic peptide (NT pro BNP), and the kappa and lambda free light chains. An increase in mean LSM was seen in all patients. Pearson correlation analysis showed a statistically significant correlation between LSM and liver volume (r = 0.78, p = 0.007) and kappa chain level (r = 0.65, p = 0.04). Interestingly, LSM did not correlate significantly with SSM (r = 0.45, p = 0.18), liver span (r = 0.57, p = 0.08), or serum ALP (r = 0.60, p = 0.07). However, LSM correlated significantly with serum ALP when corrected for liver volume (partial correlation, r = 0.71, p = 0.03) and NT pro BNP levels (partial correlation, r = 0.68, p = 0.04). MRI review revealed that amyloid deposition in the liver can be diffuse, lobar, or focal. MRE is useful for the evaluation of hepatic amyloidosis and shows increased stiffness in hepatic amyloidosis. MRE has the potential to be a non-invasive quantitative imaging marker for hepatic amyloidosis.
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
Gangat, Naseema , Marinaccio, Christian , Swords, Ronan , Watts, Justin M. , Rademaker, Alfred , Fought, Angela J. , Frankfurt, Olga, Altman, Jessica K. , Wen, Qiang , Farnoud, Noushin , Famulare, Christopher , Patel, Akshar, Vallapureddy, Rangit, Barath, Stephanie, Graf, Amy, Handlogten, Amy, Zblewski, Darci, Patnaik, Mrinal M. , Al‐Kali, Aref , Dinh, Yvonne, Prahl, Kristen Englund, Patel, Shradha, Nobrega, Juan Carlos , Tejera, Dalissa, Thomassen, Amber , Gao, Juehua , Rampal, Raajit K. , Tefferi, Ayalew , Stein, Brady L. , Crispino, John D. , Vallapureddy, Rangit R, Rampal, Raajit K , Giles, Francis Joseph , Crispino, John D , Gurbuxani, Sandeep K. , Wen, Qiang Jeremy, TAPIA-CONYER, ROBERTO C. , Ji, Peng Cheng

Mayo Clinic

Clinical Cancer Research | May 7, 2019 | Volume: 25 | Issue: 16 | Pages: 4898-4906

10.1158/1078-0432.ccr-19-1005 | PMID 31061068 Get It

Abstract Purpose: Myelofibrosis is characterized by bone marrow fibrosis, atypical megakaryocytes, splenomegaly, constitutional symptoms, thrombotic and hemorrhagic complications, and a risk of evolution to acute leukemia. The JAK kinase inhibitor ruxolitinib provides therapeutic benefit, but the effects are limited. The purpose of this study was to determine whether targeting AURKA, which has been shown to increase maturation of atypical megakaryocytes, has potential benefit for patients with myelofibrosis. Patients and Methods: Twenty-four patients with myelofibrosis were enrolled in a phase I study at three centers. The objective of the study was to evaluate the safety and preliminary efficacy of alisertib. Correlative studies involved assessment of the effect of alisertib on the megakaryocyte lineage, allele burden, and fibrosis. Results: In addition to being well tolerated, alisertib reduced splenomegaly and symptom burden in 29% and 32% of patients, respectively, despite not consistently reducing the degree of inflammatory cytokines. Moreover, alisertib normalized megakaryocytes and reduced fibrosis in 5 of 7 patients for whom sequential marrows were available. Alisertib also decreased the mutant allele burden in a subset of patients. Conclusions: Given the limitations of ruxolitinib, novel therapies are needed for myelofibrosis. In this study, alisertib provided clinical benefit and exhibited the expected on-target effect on the megakaryocyte lineage, resulting in normalization of these cells and reduced fibrosis in the majority of patients for which sequential marrows were available. Thus, AURKA inhibition should be further developed as a therapeutic option in myelofibrosis. See related commentary by Piszczatowski and Steidl, p. 4868
POEMS Syndrome: 2019 Update on diagnosis, risk‐stratification, and management
Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | April 23, 2019 | Volume: 94 | Issue: 7 | Pages: 812-827

10.1002/ajh.25495 | PMID 31012139 Get It

AbstractDisease OverviewPolyneuropathy, organomegaly, endocrinopathy, M‐protein, skin changes (POEMS) syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Diagnoses are often delayed because the syndrome is rare and can be mistaken for other neurologic disorders, most commonly chronic inflammatory demyelinating polyradiculoneuropathy. POEMS syndrome should be distinguished from the Castleman disease variant of POEMS syndrome, which has no clonal PCD and typically little to no peripheral neuropathy but has several of the minor diagnostic criteria for POEMS syndrome.DiagnosisThe diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal PCD, and at least one of the minor criteria.Risk StratificationBecause the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR.Risk‐Adapted TherapyFor those patients with a dominant sclerotic plasmacytoma, first line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement and for those who have progression of their disease 3 to 6 months after completing radiation therapy should receive systemic therapy. Corticosteroids are temporizing, but alkylators are the mainstay of treatment, either in the form of low dose conventional therapy or high dose with stem cell transplantation. Lenalidomide shows promise with manageable toxicity. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.
Higher CD3 cell counts in apheresis collection in relation to superior survival in patients with multiple myeloma.
Kim, Sharon , Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Gastineau, Dennis A., Porrata, Luis F. , Kumar, Shaji , Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Winters, Jeffrey L. , Gastineau, Dennis A. , Hogan, William J.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 11085-11085

10.1200/jco.2015.33.15_suppl.11085 Get It

Implementation of a supervised exercise rehabilitation program in breast cancer survivors to improve quality of life, exercise endurance and fatigue in a rural oncology clinic.
Adams, Angela D., Harris, R. Scott , Vaughan, Brian , Srinivasan, Sridhar, Sheqwara, Jawad , Jha, Asit, Harris, Rose, Srinivasan, Sridhar

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e20615-e20615

10.1200/jco.2015.33.15_suppl.e20615 Get It

Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment.
Kourelis, Taxiarchis , Kyle, Robert A. , Kumar, Shaji , Lacy, Martha Q. , Kapoor, Prashant , Lust, John A., Hayman, Suzanne R. , Zeldenrust, Steven R., Gertz, Morie A. , Buadi, Francis K. , Go, Ronald S. , Rajkumar, S. Vincent , Dingli, David , Lin, Yi , Leung, Nelson , Dispenzieri, Angela

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8594-8594

10.1200/jco.2015.33.15_suppl.8594 Get It

Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma following early high dose therapy and autologous hematopoietic cell transplantation (SCT).
Kaufman, Gregory P., Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Kumar, Shaji , Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8583-8583

10.1200/jco.2015.33.15_suppl.8583 Get It